10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 10-Q

Quarterly Report Under Section 13 or 15(d) of

The Securities Exchange Act of 1934

For quarter ended: June 30, 2013 Commission File No. 0-11178

UTAH MEDICAL PRODUCTS, INC.

(Exact name of Registrant as specified in its charter)

UTAH	87-0342734
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

7043 South 300 West

Midvale, Utah  84047

Address of principal executive offices

Registrant's telephone number:   (801) 566-1200

      Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and; (2) has been subject to such filing requirements for the past 90 days.   Yes x   No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o Accelerated filer x Non-accelerated filer o Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes o   No x

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).   Yes xNo o

Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of August 7, 2013: 3,735,000

UTAH MEDICAL PRODUCTS, INC.

INDEX TO FORM 10-Q

PART I - FINANCIAL INFORMATION			PAGE
	Item 1.	Financial Statements
		Consolidated Condensed Balance Sheets as of June 30, 2013 and December 31, 2012	1
		Consolidated Condensed Statements of Income for the  three and six months ended June 30, 2013 and June 30, 2012	2
		Consolidated Condensed Statements of Cash Flows for the six months ended June 30, 2013 and June 30, 2012	3
		Notes to Consolidated Condensed Financial Statements	4
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	6
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	13
	Item 4.	Controls and Procedures	13
PART II – OTHER INFORMATION
	Item 1.	Legal Proceedings	14
	Item 1A.	Risk Factors	14
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	15
	Item 6.	Exhibits	16
SIGNATURES			16

PART I - FINANCIAL INFORMATION
Item 1.  Financial Statements
UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED BALANCE SHEETS AS OF
JUNE 30, 2013 AND DECEMBER 31, 2012
(in thousands)
	(unaudited)			(audited)
ASSETS	JUNE 30, 2013			DECEMBER 31, 2012
Current assets:
Cash	$	11,385		$	8,871
Investments, available-for-sale		51			42
Accounts & other receivables - net		5,673			4,341
Inventories		4,367			4,353
Other current assets		813			929
Total current assets		22,289			18,535
Property and equipment - net		8,155			8,428
Goodwill		14,953			15,488
Other intangible assets		38,731			41,242
Other intangible assets - accumulated amortization		(7,699	)		(6,758	)
Other intangible assets - net		31,031			34,484
TOTAL	$	76,429		$	76,935
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	942		$	1,000
Accrued expenses		3,831			2,821
Current portion of notes payable		3,834			4,001
Total current liabilities		8,607			7,823
Notes payable		6,709			9,003
Deferred tax liability - intangible assets		7,583			7,889
Other long term liabilities		-			363
Deferred income taxes		889			884
Total liabilities		23,788			25,963
Stockholders' equity:
Preferred stock - $.01 par value; authorized - 5,000  shares; no shares issued or outstanding		-			-
Common stock - $.01 par value; authorized - 50,000 shares; issued - June 30, 2013, 3,728 shares and  December 31, 2012, 3,703 shares		37			37
Accumulated other comprehensive loss		(3,343	)		(851	)
Additional paid-in capital		2,885			2,268
Retained earnings		53,062			49,519
Total stockholders' equity		52,641			50,972
TOTAL	$	76,429		$	76,935

see notes to consolidated condensed financial statements

1

UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF INCOME FOR THE
THREE AND SIX MONTHS ENDED JUNE 30, 2013 AND JUNE 30, 2012
(in thousands, except per share amounts - unaudited)
	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2013			2012			2013			2012
Sales, net	$	10,002		$	10,025		$	20,376		$	21,230
Cost of goods sold		3,954			3,954			8,047			8,421
Gross profit		6,048			6,071			12,329			12,809
Operating expense
Selling, general and administrative		2,213			2,372			4,482			4,850
Research & development		120			147			243			293
Total		2,333			2,519			4,725			5,143
Operating income		3,715			3,552			7,605			7,667
Other income (expense)		(89	)		(122	)		(191	)		(300	)
Income before provision for income taxes		3,627			3,430			7,414			7,367
Provision for income taxes		994			1,029			2,046			2,177
Net income	$	2,632		$	2,401		$	5,368		$	5,190
Earnings per common share (basic)	$	0.71		$	0.65		$	1.44		$	1.42
Earnings per common share (diluted)	$	0.70		$	0.65		$	1.43		$	1.41
Shares outstanding - basic		3,725			3,678			3,718			3,663
Shares outstanding - diluted		3,770			3,711			3,764			3,694
Other comprehensive income:
Foreign currency translation net of taxes of  $0 in all periods	$	19		$	(949	)	$	(2,497	)	$	244
Unrealized gain (loss) on investments net of taxes of $2, $(3), $4 and $3		2			(5	)		5			4
Total comprehensive income	$	2,654		$	1,447		$	2,876		$	5,438

see notes to consolidated condensed financial statements

2

UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
FOR THE SIX MONTHS ENDED JUNE 30, 2013 AND JUNE 30, 2012
(in thousands - unaudited)
	Six Months Ended June 30,
	2013			2012
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	5,368		$	5,190
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation		308			334
Amortization		1,273			1,305
(Gain) loss on investments		-			-
Provision for (recovery of) losses on accounts receivable		(1	)		8
(Gain)/Loss on disposal of assets		(1	)		-
Deferred income taxes		(357	)		(428	)
Stock-based compensation expense		14			38
Changes in operating assets and liabilities:
Accounts receivable - trade		(1,350	)		(275	)
Accrued interest and other receivables		(128	)		(89	)
Inventories		8			183
Prepaid expenses and other current assets		145			62
Accounts payable		(17	)		429
Accrued expenses		169			(170	)
Deferred revenue		(50	)		(50	)
Other liability		(339	)		-
Total adjustments		(326	)		1,347
Net cash provided by operating activities		5,042			6,537
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures for:
Property and equipment		(111	)		(133	)
Intangible assets		(5	)		(1	)
Purchases of investments		-			-
Proceeds from sale of investments		-			-
Net cash (used in) provided by investing activities		(116	)		(134	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock - options		490			978
Common stock purchased and retired		-			-
Payment of taxes for exchange of stock options		(90	)		-
Tax benefit attributable to exercise of stock options		199			99
Repayment of notes payable		(1,935	)		(5,221	)
Payment of dividends		(911	)		(878	)
Net cash provided by (used in) financing activities		(2,246	)		(5,021	)
Effect of exchange rate changes on cash		(164	)		(3	)
NET INCREASE IN CASH		2,514			1,378
CASH AT BEGINNING OF PERIOD		8,871			6,534
CASH AT END OF PERIOD	$	11,385		$	7,913
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for income taxes	$	1,634		$	2,021
Cash paid during the period for interest		235			360

see notes to consolidated condensed financial statements

3

UTAH MEDICAL PRODUCTS, INC.

NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

(unaudited)

(1)       The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States.  These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10-K for the year ended December 31, 2012.  In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations.  Currency amounts are in thousands except per-share amounts and where noted.

(2)       Inventories at June 30, 2013 and December 31, 2012 consisted of the following:

	June 30,		December 31,
	2013		2012
Finished goods	$	1,487	$	1,630
Work-in-process		1,031		938
Raw materials		1,849		1,785
Total	$	4,367	$	4,353

(3)      Stock-Based Compensation. The Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors.  The Company accounts for stock compensation under FASB Accounting Standards Codification (“ASC”) 718, Stock Compensation.  This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors.  In the quarters ended June 30, 2013 and 2012, the Company recognized $7 and $18, respectively, in stock-based compensation cost.  In the six months ended June 30, 2013 and 2012, the Company recognized $14 and $38, respectively, in stock-based compensation cost.

(4)     Notes payable.  In March 2011, the Company obtained a $14,000 loan from JPMorgan Chase Bank, N.A. (Chase), to help finance the purchase of Femcare Group Ltd (Femcare) of the United Kingdom, and its subsidiaries. The terms and conditions of the loan require UTMD to a) repay the loan principal in equal monthly payments over 5 years, b) pay interest based on the 30-day LIBOR rate plus a margin starting at 2.80% and ranging from 2.00% to 3.75%, depending on the ratio of UTMD’s funded debt to EBITDA (Leverage Ratio), c) pledge 65% of all foreign subsidiaries’ stock, d) provide first priority liens on all domestic business assets, e) maintain UTMD’s Interest Coverage Ratio at 1.15 to 1.00 or better, f) maintain UTMD’s Tangible Net Worth (TNW) above a minimum threshold 20% below TNW at closing on March 18, and g) maintain UTMD’s Leverage Ratio at 2.75 to 1.00 or less. UTMD is in compliance with all of the loan covenants at June 30, 2013. Based on UTMD’s financial position, the bank’s margin was 2.00% at June 30, 2013. The principal balance on this note at June 30, 2013 was $3,850.

In March 2011, the Company also obtained a $12,934 loan from JP Morgan Chase, London Branch, to help finance UTMD’s purchase of Femcare. Terms and conditions of the UK loan are the same as those listed above for the $14,000 U.S. loan.  The principal balance on this note at June 30, 2013 was $6,693.

(5) Warranty Reserve.   The Company’s published warranty is: “UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment.  During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.”

UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2012 or June 30, 2013.

4

(6)  Investments.  As of June 30, 2013, the Company’s investments are in Citigroup (C).  Changes in the unrealized holding gain on investment securities available-for-sale and reported as a separate component of accumulated other comprehensive income are as follows:

		2Q 2013		2Q 2012
Balance, beginning of period	$	3	$	(183	)
Realized loss from securities included in beginning balance		-		-
Gross unrealized holding gains (losses), in equity securities		4		(8)
Deferred income taxes on unrealized holding (gain) loss		(2)		3
Balance, end of period	$	5	$	(188	)

(7)  Fair Value Measurements.  The Company follows ASC 820, Fair Value Measurement to determine fair value of its financial assets.  The following table provides financial assets carried at fair value measured as of June 30, 2013:

			Fair Value Measurements Using
Description	Total Fair Value at 6/30/2013		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other  Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3 )
Equities	$	51	$	51	$	0	$	0

(8)       Subsequent Events.UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.

5

Item 2.  Management's Discussion and Analysis of Financial Condition and Results of Operations

General

UTMD manufactures and markets a well-established range of specialty medical devices.  The Company’s Form 10-K Annual Report for the year ended December 31, 2012 provides a detailed description of products, technologies, markets, regulatory issues, business initiatives, resources and business risks, among other details, and should be read in conjunction with this report.  Because of the relatively short span of time, results for any given three month period in comparison with a previous three month period may not be indicative of comparative results for the year as a whole.  Currency amounts in the report are in thousands, except per-share amounts or where otherwise noted.

Analysis of Results of Operations

a)     Overview

  In the second calendar quarter (2Q) and first half (1H) of 2013, gross profit margins were consistent with the same periods in the prior year while operating income, income before taxes and net income margins all improved, as follows:

	2Q 2013		2Q 2012		1H 2013		1H 2012
Gross Profit Margin (gross profit/ sales):	60.5	%	60.6	%	60.5	%	60.3	%
Operating Income Margin (operating profit/ sales):	37.1	%	35.4	%	37.3	%	36.1	%
EBT Margin (profit before income taxes/ sales):	36.3	%	34.2	%	36.4	%	34.7	%
Net Income Margin (profit after taxes/ sales):	26.3	%	24.0	%	26.3	%	24.4	%

UTMD’s operating income margin (OPM) improved despite the new Medical Device Excise Tax (MDET), imposed as a component of the Patient Protection and Affordable Care Act (Obamacare).  The MDET, levied as 2.3% of domestic sales of medical devices, is included in sales and marketing expenses.

In 2Q 2013, revenues and gross profits were consistent with those in 2Q 2012, while in 1H 2013, they were lower as a result of the previously reported distributor overstocking in 1Q 2012.  Nevertheless, UTMD was able to improve its income before tax, net income and earnings per share in both 2Q 2013 and 1H 2013 periods compared to the same periods in 2012, as follows:

		2Q 2013		2Q 2012	change				1H 2013		1H 2012	change
Net Sales	$	10,002	$	10,025		(0.2	%)	$	20,376	$	21,230		(4.0	%)
Gross Profit		6,048		6,071		(0.4	%)		12,329		12,809		(3.7	%)
Operating Income		3,715		3,552		4.6	%		7,605		7,667		(0.8	%)
Income Before Tax		3,627		3,430		5.7	%		7,414		7,367		0.6	%
Net Income		2,632		2,401		9.6	%		5,368		5,190		3.4	%
Earnings per Diluted Share		.698		.647		7.9	%		1.426		1.405		1.5	%

Operating expenses were $2,333 (23.3% of sales) in 2Q 2013 compared to $2,519 (25.1% of sales) in 2Q 2012, and $4,725 (23.2% of sales) in 1H 2013 compared to $5,143 (24.2% of sales) in 1H 2012. Average quarterly operating expenses were $2,528 (24.3% of sales) in the full year of 2012.

Income before taxes (EBT) was $3,627 (36.3% of sales) in 2Q 2013 compared to $3,430 (34.2% of sales) in 2Q 2012, and was $7,414 (36.4% of sales) in 1H 2013 compared to $7,367 (34.7% of sales) in 1H 2012.  Average quarterly EBT was $3,634 (35.0% of sales) in the full year of 2012.  In addition to the improvement in OPM, 2Q and 1H 2013 EBT benefited from lower interest expense on lower loan principal balances.

Net Income (NP) was $2,632 (26.3% of sales) in 2Q 2013 compared to $2,401 (24.0% of sales) in 2Q 2012, and $5,368 (26.3% of sales) in 1H 2013 compared to $5,190 (24.4% of sales) in 1H 2012. Average quarterly NP was $2,542 (24.5% of sales) in the full year of 2012. The improvement in UTMD’s Net Income margin was leveraged by a lower consolidated income tax provision.  The income tax provision rate was 27.4% in 2Q 2013 compared to 30.0% in 2Q 2012, and 27.6% in 1H 2013 compared to 29.6% in 1H 2012.

6

Earnings per share (EPS) were $.698 in 2Q 2013 compared to $.647 in 2Q 2012, and $1.426 in 1H 2013 compared to $1.405 in 1H 2012. Earnings per share averaged $.685 per quarter for the full year of 2012.  Diluted shares used to calculate EPS increased to 3,769,600 in 2Q 2013 from 3,710,800 in 2Q 2012, and to 3,763,800 in 1H 2013 from 3,693,600 in 1H 2012.  The increases were due to the exercise of employee options and the higher dilution factor applied to unexercised options as a result of a much higher average market price of UTMD stock. The number of shares added as a dilution factor in 2Q 2013 was 44,500 compared to 32,800 in 2Q 2012, and 45,600 in 1H 2013 compared to 30,100 in 1H 2012.

The changes in UTMD’s Balance Sheet at June 30, 2013 from December 31, 2012 resulted primarily from continued excellent cash generation from operations, reduction in debt, a stronger U.S. Dollar (USD) which resulted in lower USD value of foreign subsidiary assets, and the early payment of the 4Q 2012 cash dividend to shareholders in December 2012 instead of January 2013, in contrast to other quarters in which the dividend is paid early in the following quarter.

b)     Revenues

The Company believes that revenue should be recognized at the time of shipment as title generally passes to the customer at the time of shipment, or completion of services performed under contract.  Revenue recognized by UTMD is based upon documented arrangements and fixed contracts in which the selling price is fixed prior to acceptance and completion of an order.  Revenue from product or service sales is generally recognized at the time the product is shipped or service completed and invoiced, and collectibility is reasonably assured.  There are no post-shipment obligations which have been or are expected to be material to financial results.

There are circumstances under which revenue may be recognized when product is not shipped, which meet the criteria of SAB 104:  the Company provides engineering services, for example, design and production of manufacturing tooling that may be used in subsequent UTMD manufacturing of custom components for other companies.  This revenue is recognized when UTMD’s service has been completed according to a fixed contractual agreement.

Terms of sale are established in advance of UTMD’s acceptance of customer orders.  In the U.S., Ireland, UK and Australia, UTMD generally accepts orders directly from and ships directly to end user clinical facilities, as well as third party med/surg distributors, under UTMD’s Standard Terms and Conditions (T&C) of Sale. About 15% of UTMD’s domestic end user sales go through third party med/surg distributors which contract separately with clinical facilities to provide purchasing, storage and scheduled delivery functions for the applicable facility. UTMD’s T&C of Sale are substantially the same in the U.S., Ireland, UK and Australia.

UTMD may have separate discounted pricing agreements with a clinical facility or group of affiliated facilities based on volume of purchases.  Pricing agreements with clinical facilities, or groups of affiliated facilities, if applicable, are established in advance of orders accepted or shipments made.  For existing customers, past actual shipment volumes determine the fixed price by part number for the next agreement period of one or two years.  For new customers, the customer’s best estimate of volume is accepted by UTMD for determining the ensuing fixed prices for the agreement period.  New customers typically have one-year agreements. Prices are not adjusted after an order is accepted. For the sake of clarity, the separate pricing agreements with clinical facilities based on volume of purchases disclosure is not inconsistent with UTMD’s disclosure above that the selling price is fixed prior to the acceptance of a specific customer order.

Total consolidated 2Q 2013 sales were $23 (0%) lower, and 1H 2013 sales were $854 (4%) lower than in the same periods of 2012.  The global consolidated sales comparisons of 2Q 2013 to 2Q 2012, and 1H 2013 to 1H 2012, were negatively affected by the currency exchange impact of a stronger U.S. Dollar (USD or $) relative to the British Pound (GBP) and the Australian Dollar (AUD). The GBP was about 3% weaker in the 2Q and about 2% weaker for the 1H.  The AUD was about 1% weaker in the 2Q and about 2% weaker for the 1H.  In contrast, the Euro was about 2% stronger in the 2Q and about the same for the 1H.  If currency exchange rates in 2013 had been the same as in 2012, consolidated sales would have been about $44 higher in 2Q 2013, and about $103 higher in 1H 2013.

7

U.S. domestic sales were $100 (2%) higher in 2Q 2013 than in 2Q 2012, and $518 (5%) lower in 1H 2013 than in 1H 2012.  Sales of Femcare’s Filshie Clip System devices to Cooper Surgical Inc. for distribution in the U.S. were 97% higher in 2Q 2013 compared to 2Q 2012, and 6% lower in 1H 2013 compared to 1H 2012. Filshie Clip System sales to Cooper were 22% of total domestic sales in 2Q 2013 compared to 11% in 2Q 2012.  Filshie Clip System sales to Cooper were 22% of total domestic sales in both 1H 2013 and 1H 2012.

International sales were $123 (2%) lower in 2Q 2013 than in 2Q 2012, and were $336 (3%) lower in 1H 2013 than in 1H 2012.  About 36% of the 2Q decline and 31% of the 1H decline was due to currency exchange. In USD terms, international sales were 51% of total consolidated 2Q 2013 sales compared to 53% in 2Q 2012, and 52% of total consolidated sales in 1H 2013 compared to 51% in 1H 2012.

UTMD’s Ireland subsidiary’s 2Q 2013 trade shipments (excludes intercompany sales), which are all in the “international sales” category, were $219 (26%) higher - 22% higher in EURO terms - compared to 2Q 2012, and in 1H 2013 were $288 (15%) higher - 14% higher in EURO terms - compared to 1H 2012.

UTMD’s Femcare UK subsidiary’s 2Q 2013 trade shipments (excludes intercompany sales), some of which are included in the “domestic sales” category, i.e. sales of the Filshie Clip System to COO, and the rest of which are included in the “international sales” category, were $159 (5%) higher - 8% higher in Great Britain Pounds (GBP) terms - compared to 2Q 2012, and in 1H 2013 were $695 (10%) lower - 8% lower in GBP terms - compared to 1H 2012.

UTMD’s Femcare Australia subsidiary’s 2Q 2013 trade shipments, which are in the “international sales” category, $2 (0%) higher -  2% higher in Australia Dollar (AUD) terms - compared to 2Q 2012, and for 1H 2013 were $131 (8%) lower - 6% lower in AUD terms - compared to 1H 2012.

The following table provides USD sales amounts divided into general product categories for total sales and the subset of international sales:

Global revenues by product category:

		2Q 2013		2Q 2012		1H 2013		1H 2012
Obstetrics	$	1,192	$	1,259	$	2,406	$	2,542
Gynecology/ Electrosurgery/ Urology		5,762		5,411		11,638		12,066
Neonatal		1,319		1,647		2,861		3,248
Blood Pressure Monitoring and Accessories*		1,729		1,708		3,471		3,374
Total:	$	10,002	$	10,025	$	20,376	$	21,230

*includes molded components sold to OEM customers.

International revenues by product category:

		2Q 2013		2Q 2012		1H 2013		1H 2012
Obstetrics	$	128	$	127	$	258	$	293
Gynecology/ Electrosurgery/ Urology		3,623		3,813		7,331		7,737
Neonatal		277		317		659		587
Blood Pressure Monitoring and Accessories*		1,113		1,008		2,255		2,222
Total:	$	5,141	$	5,265	$	10,503	$	10,839

*includes molded components sold to OEM customers.

c)     Gross Profit

Gross profits (GP) result from subtracting the cost of manufacturing products (direct materials, direct labor and manufacturing overhead), or the purchase price of finished products which are resold, from revenues. UTMD’s gross profit margin (GPM) is gross profit as a percentage of revenues.  In 2Q 2013, GP were $6,048 (60.5% GPM) compared to $6,071 (60.6% GPM) in 2Q 2012. In 1H 2013, GP were $12,329 (60.5% GPM) compared to $12,809 (60.3% GPM) in 1H 2012. The small changes in GPM in the various periods were due essentially to product mix differences.

8

d)    Operating Income

Operating income is the profit remaining after subtracting operating expenses from GP.  UTMD’s operating profit margin (OPM) is its operating income divided by revenues.  Operating income in 2Q 2013 was $3,715 (37.1% OPM) compared to $3,552 (35.4% OPM) in 2Q 2012.  In 1H 2013, operating income was $7,605 (37.3% OPM) compared to $7,667 (36.1% OPM) in 1H 2012.  A higher OPM with lower sales represents strong operational performance.

Operating expenses include sales and marketing (S&M) expenses, product development (R&D) expenses and general and administrative (G&A) expenses.  Consolidated operating expenses were $186 lower in 2Q 2013 and $418 lower in 1H 2013 compared to the same periods of 2012, despite $71 added to 2Q 2013, and $146 to 1H 2013, operating expenses for the Obamacare MDET that weren’t part of 2012 operating expenses. A stronger USD helped reduce operating expenses when consolidating the operating expenses of foreign subsidiaries into USD terms.

Consolidated S&M expenses in 2Q 2013 were $677 (6.8% of sales) compared to $703 (7.0% of sales) in 2Q 2012, and were $1,346 (6.6% of sales) in 1H 2013 compared to $1,354 (6.4% of sales) in 1H 2012. 2Q and 1H 2013 S&M expenses included the MDET.  (In financial projections for 2013 included in UTMD’s 2012 SEC Form 10-K, management included the MDET in non-operating expenses. The change in classification from non-operating to operating expenses, more specifically S&M expenses, was the result of a recommendation by UTMD’s independent accounting firm.)  S&M expenses include all customer support costs including training. In general, training is not required for UTMD’s products since they are well-established and have been clinically widely used. Written “Instructions For Use” are packaged with all finished devices. Although UTMD does not have any explicit contracts with customers to provide training, it does have third party group purchasing organization agreements in the U.S. and UK under which it agrees to provide hospital members inservice and clinical training as required and reasonably requested.

UTMD promises prospective customers that it will provide, at no charge in reasonable quantities, copies of videotapes and other instruction materials developed for the use of its products. UTMD provides customer support from offices in the U.S., UK, Ireland and Australia by telephone, and employed representatives on a geographically dispersed basis, to answer user questions and help troubleshoot any user issues. Occasionally, on a case-by-case basis, UTMD may utilize the services of an independent practitioner to provide educational assistance to clinicians. All inservice and training expenses are routinely expensed as they occur.  Except for the consulting services of independent practitioners, all of these services are allocated from fixed S&M overhead costs included in Operating Expenses.  Historically, marginal consulting costs have been immaterial to financial results.

R&D expenses in 2Q 2013 were $120 (1.2% of sales) compared to $147 (1.5% of sales) in 2Q 2012, and were $243 (1.2% of sales) in 1H 2013 compared to $293 (1.4% of sales) in 1H 2012.  The differences were due to normal period to period fluctuations in project costs.

Consolidated G&A expenses in 2Q 2013 were $1,536 (15.4% of sales) compared to $1,670 (16.7% of sales) in 2Q 2012, and were $3,136 (15.4% of sales) in 1H 2013 compared to $3,496 (16.5% of sales) in 1H 2012. The G&A expenses included $621 (6.2% of sales) in 2Q 2013 and $1,246 (6.1% of sales) in 1H 2013 of non-cash expense from the amortization of identifiable intangible assets (IIA) resulting from the Femcare acquisition, which were $639 (6.4% of sales) in 2Q 2012 and $1,274 (6.0% of sales) in 1H 2012. The differences were due to currency exchange, as the amortization of IIA of the Femcare acquisition is in constant GBP. In addition to the reduction in foreign operating expense due to a stronger USD, lower G&A expenses were primarily the result of 1) lower litigation expense in the U.S.; 2) lower UK expense from lower leases and rents compared to the prior year, and a foreign currency exchange gain on UK accounts receivable; and 3) lower variable expenses in Australia related to lower sales activity, lower fees negotiated in a service agreement and a reclassification of Australia freight expense included in G&A in 2012 to S&M expense in 2013.

9

 In addition to litigation costs, G&A expenses include the cost of outside financial auditors and corporate governance activities relating to the implementation of SEC rules resulting from the Sarbanes-Oxley Act of 2002, as well as estimated stock-based compensation cost, a noncash expense. Option compensation expense included in G&A expenses was $7 in 2Q 2013 compared to $18 in 2Q 2012, and $14 in 1H 2013 compared to $38 in 1H 2012.

Operating expense summary:

		2Q 2013		2Q 2012		1H 2013		1H 2012
S&M Expense	$	677	$	702	$	1,346	$	1,354
R&D Expense		120		147		243		293
G&A Expense		1,536		1,670		3,136		3,496
Total Operating Expenses:	$	2,333	$	2,519	$	4,725	$	5,143

e)     Non-operating income/ expense

Non-operating income (NOI) includes income from rent of underutilized property, investment income and royalties received from licensing the Company’s technology.  Non-operating expense (NOE) includes loan interest and bank fees.  UTMD’s reported NOE is the net of its NOE and NOI. The net is a NOE because the amount of interest that UTMD has been paying on bank loans since the 2011 Femcare acquisition exceeds the sum of all of its NOI. (Net) NOE in 2Q 2013 was $89 compared to $122 in 2Q 2012, and was $191 in 1H 2013 compared to $300 in 1H 2012. The decreases were primarily due to lower interest expense on bank loans.  In the absence of adding debt to help fund additional acquisitions that improve shareholder value, NOE will continue to decline as UTMD repays its current bank loans.

f)     Income Before Income Taxes

Income before taxes (EBT) results from subtracting NOE from operating income.  EBT Margin (EBTM) is EBT divided by revenues.  2Q 2013 consolidated EBT was $3,627 (36.3% EBTM) compared to $3,430 (34.2% EBTM) in 2Q 2012. 1H 2013 consolidated EBT was $7,414 (36.4% EBTM) compared to $7,367 (34.7% EBTM) in 1H 2012. The EBT of UTMD Ltd. (Ireland) was €225 (27.0% EBTM) in 2Q 2013 compared to €157 (23.1% EBTM) in 2Q 2012, and was €452 (25.6% EBTM) in 1H 2013 compared to €279 (18.2% EBTM) in 1H 2012. The EBT of Femcare (Femcare-Nikomed, Ltd., UK and Femcare Australia) was £1,028 (39.5% EBTM) in 2Q 2013 compared to £722 (30.0% EBTM) in 2Q 2012, and was £2,058 (39.2% EBTM) in 1H 2013 compared to £1,999 (35.3% EBTM) in 1H 2012.

Excluding the noncash effects of depreciation, amortization of intangible assets, write-off of impaired assets and stock option expense, 2Q 2013 and 1H 2013 consolidated EBT plus interest expense were $4,535 and $9,245, respectively.  Excluding the noncash effects of depreciation, amortization of intangible assets, write-off of impaired assets and stock option expense, the last twelve months’ consolidated EBT plus interest expense were $18,544.

g)     Net Income

Net Income results from subtracting UTMD’s accrued income tax provision from EBT.  Net income divided by revenues is UTMD’s net income margin (NPM). Consolidated net income was $2,632 (26.3% NPM) in 2Q 2013 compared to $2,401 (24.0% of sales) in 2Q 2012, and was $5,368 (26.3% NPM) in 1H 2013 compared to $5,190 (24.4% of sales) in 1H 2012.  The improvement in 2013 NPMs compared to 2012 was due to the improvement in OPM and EBTM described above, plus a greater portion of total EBT achieved in Ireland, the lowest taxed sovereignty, and a lower corporate income tax rate in the UK.  The consolidated income tax provision rate was 27.4% in 2Q 2013 compared to 30.0% in 2Q 2012, and 27.6% in 1H 2013 compared to 29.6% in 1H 2012.

h)     Earnings Per Share

Earnings per share (EPS) are Net Income divided by the number of shares of stock outstanding (diluted to take into consideration stock option awards which are “in the money,” i.e., have exercise prices below the applicable period’s weighted average market value). Diluted EPS were $0.698 in 2Q 2013 compared to $0.647 in 2Q 2012, and $1.426 in 1H 2013 compared to $1.405 in 1H 2012.  EPS for the most recent twelve months were $2.76.

2Q 2013 EPS increased 5.1 cents (8%) compared to 2Q 2012 as a result of improved profit margins and lower corporate income tax rate in the UK. For 1H 2013, EPS increased 2.1 cents (1%) compared to 1H 2012.

10

2Q 2013 weighted average number of diluted common shares (the number used to calculate diluted EPS) were 3,769,600 compared to 3,710,800 shares in 2Q 2012, and 3,763,800 in 1H 2013 compared to 3,693,600 in 1H 2012.  Employees exercised options for 6,400 shares in 2Q 2013 and for 38,440 shares in 1H 2013.  Options outstanding at June 30, 2013 were 109,400 shares at an average exercise price of $27.01 per share, including shares awarded but not vested. This compares to 183,500 unexercised option shares outstanding at June 30, 2012.

Increases and decreases in UTMD’s stock price impact EPS as a result of the dilution calculation for unexercised options with exercise prices below the average stock market value during each period. The dilution calculation added 44,500 shares to actual weighted average shares outstanding in 2Q 2013 compared to 32,800 in 2Q 2012, and 45,600 shares to the 1H 2013 calculation compared to 30,100 in 1H 2012.  Actual outstanding common shares as of the end of 2Q 2013 were 3,728,300 compared to 3,684,600 at the end of 2Q 2012.  The Company did not repurchase any of its shares in the open market in 1H 2013 or in 1H 2012. Notwithstanding, UTMD retains its program for repurchasing shares when they seem undervalued.

i)     Return on Equity

Return on equity (ROE) is the portion of net income retained by UTMD to internally finance its growth, divided by the average accumulated stockholder equity for the applicable time period.  Annualized ROE (after payment of dividends) in 1H 2013 was 14% compared to 16% in 1H 2012.  ROE prior to payment of dividends was 21% in 1H 2013 and 24% in 1H 2012. Even though net income was up 8% in 1H 2013, the lower ROE is due primarily to average total assets remaining about the same while debt declined by 38%.  Even after payment of cash dividends (which reduce stockholders’ equity), stockholders’ equity as of June 30, 2013 is 16% higher than at June 30, 2012.

Liquidity and Capital Resources

j)     Cash flows

Net cash provided by operating activities, including adjustments for depreciation and amortization and other non-cash expenses along with changes in working capital, totaled $5,042 in 1H 2013 compared to $6,537 in 1H 2012.  The most significant differences in the two periods were use of cash of $1,074 from a larger increase in accounts receivable and $446 from a small decrease in accounts payable in 1H 2013 compared to a large increase in 1H 2012.

The Company’s use of cash to pay down its bank loan principal balances was the most significant use of cash in either period. UTMD repaid $1,935 on its notes during 1H 2013, compared to $5,221 during 1H 2012.  All of UTMD’s notes are scheduled to be repaid by April 2016. UTMD made cash dividend payments of $911 in 1H 2013 compared to $878 in 1H 2012.

Capital expenditures for property and equipment (PP&E) were $111 in 1H 2013 compared to $133 in 1H 2012.  In contrast, depreciation of PP&E was $308 in 1H 2013 and $334 in 1H 2012.  Planned capital expenditures during 2013 are expected to be less than depreciation of PP&E.

In 1H 2013, UTMD received $490 and issued 25,205 shares of its stock upon the exercise of employee stock options, net of 13,235 shares retired upon employees trading those shares in payment of the stock option exercise price and related taxes.  Option exercises in 1H 2013 were at an average price of $26.98 per share.  In comparison, in 1H 2012, the Company received $978 from issuing 44,588 shares of stock on the exercise of employee and director stock options, net of 3,169 shares retired upon employees trading those shares in payment of the stock option exercise price.

Management believes that income from operations and effective management of working capital will provide the liquidity needed to finance its internal growth plans.  In addition, the Company may use cash for marketing or product manufacturing rights to broaden the Company's product offerings; for dividends and continued share repurchases when the price of the stock is undervalued; and if available for a reasonable price, an acquisition that might strategically fit UTMD’s business and be accretive to performance.

11

k)     Assets and Liabilities

June 30, 2013 total assets decreased $507 (less than 1%) from December 31, 2012, essentially due to a strengthening of the USD compared to the GBP and EURO. UTMD’s Ireland subsidiary assets were translated into USD at a rate 1.3% lower than the EURO to USD conversion rate at the end 2012.   UTMD’s Femcare UK subsidiary assets were translated into USD at a rate 6.9% lower than the GBP to USD conversion rate at the end of 2012.  Femcare’s June 30, 2013 intangible assets were $2,664 lower than they would have been at the December 31, 2012 GBP/USD exchange rate.  Cash increased $2,514 during 1H 2013. Accounts and other receivables increased $1,332. Inventories increased $14 and other current assets decreased $116 during 1H 2013.  Inventory and receivables balances were within management’s productivity targets.

Working capital (current assets minus current liabilities) was $13,682 at June 30, 2013, compared to $10,712 at December 31, 2012.  Current liabilities increased $784, including a $1,010 increase in accrued expenses.  The accrued expenses increase was due to the 2Q 2013 quarterly dividend payment to shareholders of $913 accrued but not paid until after June 30, whereas the 4Q 2012 dividend payment was paid before the end of December 2012.  UTMD believes that its working capital remains sufficient to meet normal operating needs, debt service requirements and cash dividend payments to shareholders.

Intangible assets (Goodwill plus Other intangible assets) decreased $3,988.  As noted above, the decrease was due to a stronger USD relative to GBP at June 30, 2013 compared to December 31, 2012 and the amortization of identifiable intangible assets of $1,246 in 1H 2013.  At June 30, 2013, net intangible assets including goodwill were 60% of total assets compared to 65% at year-end 2012.

Net property and equipment decreased $273 in 1H 2013.  Depreciation of $308 exceeded capital expenditures of $111.

UTMD’s principal balance of bank debt at June 30, 2013 was 1) $3,850 to JP Morgan Chase in the U.S., of which $2,450 is long term debt, and 2) $6,693 (£4,400) to JP Morgan Chase in the U.K., of which $4,259 (£2,800) is long term debt. The loan principal balances at June 30, 2013 declined $700 in the U.S. and £800 in the UK from the end of 2012.  The deferred tax liability balance for Femcare identifiable intangible assets ($9,084 on the date of the acquisition), was $7,583 at June 30, 2013.  Reduction of the deferred tax liability occurs as the book/tax difference of amortization is eliminated over the remaining useful life of the identifiable intangible assets. UTMD’s total debt ratio (total liabilities/ total assets) as of June 30, 2013 was 31%, compared to 34% on December 31, 2012.  UTMD’s total debt ratio on June 30, 2012 was 41%.

l)     Management's Outlook.

As outlined in its December 31, 2012 10-K report, UTMD’s plan for 2013 is to

1)  continue to exploit distribution and manufacturing synergies by further integrating capabilities and resources in its multinational operations;

2)  introduce additional gynecology products helpful to clinicians through internal new product development;

3)  continue achieving excellent overall financial operating performance;

4)  utilize positive cash generation to pay down debt, continue cash dividends to shareholders and continue open market share repurchases if/when the UTMD share price seems undervalued; and

5)  be vigilant for accretive acquisition opportunities which may be increasingly brought about by difficult burdens on small, innovative companies, including especially the MDET.

Management believes it remains on track after 1H 2013 to accomplish its previously stated objectives for 2013.

m)      Accounting Policy Changes.

None.

Forward-Looking Information.   This report contains certain forward-looking statements and information relating to the Company that are based on the beliefs of management as well as assumptions made by management based on information currently available.  When used in this document, the words “anticipate,” “believe,” “project,” “estimate,” “expect,” “intend” and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements.  Such statements reflect the current view of the Company respecting future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted throughout this document.  Although the Company has attempted to identify important factors that could cause the actual results to differ materially, there may be other factors that cause the forward statement not to come true as anticipated, believed, projected, expected, or intended.  Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those described herein as anticipated, believed, projected, estimated, expected or intended.  Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results, and the Company assumes no obligation to update or disclose revisions to those estimates.

12

Item 3. Quantitative and Qualitative Disclosures about Market Risk

  UTMD has manufacturing and trading operations, including related assets, in the U.S. denominated in the U.S. Dollar (USD), in Ireland denominated in the Euro (EUR), in England denominated in the British Pound (GBP) and in Australia denominated in the Australia Dollar (AUD).  The currencies are subject to exchange rate fluctuations that are beyond the control of UTMD.  The exchange rates were .7686, .7585 and .7892 EUR per USD as of June 30, 2013, December 31, 2012 and June 30, 2012, respectively.  Exchange rates were .6574, .6150 and .6376 GBP per USD as of June 30, 2013, December 31, 2012 and June 30, 2012, respectively.  Exchange rates were 1.0913, .9621 and .9769 AUD per USD on June 30, 2013, December 31, 2012 and June 30, 2012, respectively.  UTMD manages its foreign currency risk without separate hedging transactions by conducting as much business in local currencies as is practicable and by converting currencies to USD as transactions occur.

Item 4. Controls and Procedures

The Company’s management, under the supervision and with the participation of the Chief Executive Officer and the Principal Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) as of June 30, 2013. Based on this evaluation, the Chief Executive Officer and Principal Financial Officer concluded that, as of June 30, 2013, the Company’s disclosure controls and procedures were effective.

There were no changes in the Company’s internal controls over financial reporting that occurred during the quarter ended June 30, 2013, that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

13

PART II - OTHER INFORMATION

Item 1.  Legal Proceedings

The Company may be a party from time to time in litigation incidental to its business.  Presently, there is no litigation for which the Company believes the outcome may be material to its financial results.

Item 1A.  Risk Factors

In addition to the other information set forth in this report, investors should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in UTMD’s Annual Report on Form 10-K for the year ended December 31, 2012, which could materially affect its business, financial condition or future results.  The risks described in the Annual Report on Form 10-K are not the only risks facing the Company.  Additional risks and uncertainties not currently known to UTMD or currently deemed to be immaterial also may materially adversely affect the Company’s business, financial condition and/or operating results.

Legislative healthcare reform in the United States, as embodied in The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 (the “Acts”) adds a substantial excise tax that begins in 2013, increases administrative costs and may lead to decreased revenues:

The voluminous Acts, administrative rules to enforce the Acts and promised efforts to reform the Acts, make the U.S. medical device marketplace unpredictable, particularly for the thousands of small medical device manufacturers including UTMD that do not have the overhead structure that the large companies can afford.  To the extent that the Acts place additional burdens on small medical device companies in the form of an excise tax on medical device sales, additional oversight of marketing and sales activities and new reporting requirements, the result is likely to be negative for UTMD’s ability to effectively compete and support continued investments in new product development and marketing of specialty devices.

Increasing regulatory burdens including premarketing approval delays may result in significant loss of revenue, unpredictable costs and loss of management focus on helping the Company thrive:

The Company’s experience in 2001-2005, when the FDA sought to shut it down highlights the ongoing risk of being subject to a regulatory environment which can be arbitrary and capricious.  The risks associated with such a circumstance relate not only to the substantial costs of litigation in millions of dollars, but also loss of business, the diversion of attention of key employees for an extended period of time, from new product development and routine quality control management activities, and a tremendous psychological and emotional toll on employees.

Since the FDA reserves to itself the interpretation of which vague industry standards comprise law at any point in time, it is impossible for any medical device manufacturer to ever be confident that it is operating within the Agency’s version of the law.  The result is that companies, including UTMD, are considered guilty prior to proving their innocence.  New premarketing submission rules and substantial increases in “user fees” may increase development costs and result in delays to revenues from new or improved products.

The growth of Group Purchasing Organizations adds non-productive costs, typically weakens the Company’s marketing and sales efforts and may result in lower revenues:

GPOs, theoretically acting as bargaining agents for member hospitals, but actually collecting revenues from the companies that they are negotiating with, have made a concerted effort to turn medical devices that convey special patient safety advantages and better health outcomes, like UTMD’s, into commodities. GPOs have been granted an antitrust exemption by the U.S. Congress. Otherwise, their business model based on “kickbacks” would be a violation of law.  These bureaucratic entities do not recognize or understand the overall cost of care as it relates to safety and effectiveness of devices, and they create a substantial administrative burden that is primarily related to collection of their administrative fees.

14

As the healthcare industry becomes increasingly bureaucratic it puts smaller companies like UTMD at a competitive disadvantage:

An aging population and an extended economic recession are placing greater burdens on healthcare systems, particularly hospitals.  The length of time and number of administrative steps required in adopting new products for use in hospitals has grown substantially in recent years.  Smaller companies like UTMD typically do not have the administrative resources to deal with broad new administrative requirements, resulting in either loss of revenue or increased costs.  As UTMD introduces new products it believes are safer and more effective, it may find itself excluded from certain customers because of the existence of long term supply agreements for preexisting products, particularly from competitors which offer hospitals a broader range of products.  Restrictions used by hospital administrators to limit clinician involvement in device purchasing decisions makes communicating UTMD’s clinical advantages much more difficult.

A product liability lawsuit could result in significant legal expenses and a large award against the Company:

UTMD’s devices are frequently used in inherently risky situations to help physicians achieve a more positive outcome than what might otherwise be the case.  In any lawsuit where an individual plaintiff suffers permanent physical injury, the possibility of a large award for damages exists whether or not a causal relationship exists.

The Company’s reliance on third party distributors in some markets may result in less predictable revenues:

UTMD’s distributors have varying expertise in marketing and selling specialty medical devices.  They also sell other devices that may result in less focus on the Company’s products.

The substantial increase in debt required to finance the acquisition of Femcare Group Ltd represents an increased business risk until the debt is repaid:

While the debt will help positively leverage financial performance if UTMD maintains future performance consistent with 2012 performance, it could also negatively leverage financial performance if the Company is unable to maintain sales volume and profit margins in a competitive worldwide market for its medical devices.

The loss of one or more key employees could negatively affect UTMD performance:

In a small company with limited resources, the distraction or loss of key personnel at any point in time may be disruptive to performance.  The Company’s benefits programs, including the stock option plan approved by shareholders in May 2013, are key to recruiting and retaining talented employees.  The rapid increase in UTMD’s employee healthcare plan costs, as another example, may cause the Company to have to reduce coverages which in turn represents a risk to retaining key employees.

Item 2.   Unregistered Sales of Equity Securities and Use of Proceeds

UTMD did not purchase any of its own securities during 2Q 2013.

15

Item 6.  Exhibits

Exhibit #	SEC Reference #	Title of Document
1	31	Certification of CEO pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
2	31	Certification of Principal Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
3	32	Certification of CEO pursuant to 18 U.S.C. §1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
4	32	Certification of Principal Financial Officer pursuant to 18 U.S.C. §1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
5	101 ins	XBRL Instance
6	101.xsd	XBRL Schema
7	101.cal	XBRL Calculation
8	101.def	XBRL Definition
9	101.lab	XBRL Label
10	101.pre	XBRL Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchanges Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	UTAH MEDICAL PRODUCTS, INC.
	REGISTRANT
Date:         8/8/13	By:    /s/ Kevin L. Cornwell
	Kevin L. Cornwell
	CEO
Date:         8/8/13	By:   /s/ Paul O. Richins
	Paul O. Richins
	Principal Financial Officer

16

EX-31.1

Exhibit 31.1

CERTIFICATION OF CEO

PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Kevin L. Cornwell, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 8, 2013

/s/ Kevin L. Cornwell

Kevin L. Cornwell

Chief Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Paul O. Richins, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 8, 2013

/s/ Paul O. Richins

Paul O. Richins

Principal Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Utah Medical Products, Inc. (the “Company”) on Form 10-Q for the period ending June 30, 2013, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Kevin L. Cornwell, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Kevin L. Cornwell

Kevin L. Cornwell

Chief Executive Officer

August 8, 2013

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Utah Medical Products, Inc. (the “Company”) on Form 10-Q for the period ending June 30, 2013, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Paul O. Richins, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Paul O. Richins

Paul O. Richins

August 8, 2013

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

XML

Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables)

6 Months Ended

Jun. 30, 2013

Tables/Schedules

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

			Fair Value Measurements Using
Description		Total Fair Value at 6/30/2013		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3 )
Equities	$	51	$	51	$	0	$	0

XML

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Income Statement
Sales, net	$ 10,002	$ 10,025	$ 20,376	$ 21,230
Cost of goods sold	3,954	3,954	8,047	8,421
Gross profit	6,048	6,071	12,329	12,809
Operating expense:
Selling, general and administrative	2,213	2,372	4,482	4,850
Research and development	120	147	243	293
Total operating expense	2,333	2,519	4,725	5,143
Operating income	3,715	3,552	7,605	7,667
Other income (expense)	(89)	(122)	(191)	(300)
Income before provision for income taxes	3,627	3,430	7,414	7,367
Provision for income taxes	994	1,029	2,046	2,177
Net income	2,632	2,401	5,368	5,190
Earnings per common share (basic)	$ 0.71	$ 0.65	$ 1.44	$ 1.42
Earnings per common share (diluted)	$ 0.70	$ 0.65	$ 1.43	$ 1.41
Shares outstanding (basic)	3,725	3,678	3,718	3,663
Shares outstanding (diluted)	3,770	3,711	3,764	3,694
Other comprehensive income:
Foreign currency translation net of taxes of $0 in all periods	19	(949)	(2,497)	244
Unrealized gain (loss) on investments net of taxes of $2, $(3), $4 and $3	2	(5)	5	4
Total comprehensive income	$ 2,654	$ 1,447	$ 2,876	$ 5,438

XML

Notes Payable

6 Months Ended

Jun. 30, 2013

Notes

Notes Payable

(4)  Notes payable.  In March 2011, the Company obtained a $14,000 loan from JPMorgan Chase Bank, N.A. (Chase), to help finance the purchase of Femcare Group Ltd (Femcare) of the United Kingdom, and its subsidiaries. The terms and conditions of the loan require UTMD to a) repay the loan principal in equal monthly payments over 5 years, b) pay interest based on the 30-day LIBOR rate plus a margin starting at 2.80% and ranging from 2.00% to 3.75%, depending on the ratio of UTMD’s funded debt to EBITDA (Leverage Ratio), c) pledge 65% of all foreign subsidiaries’ stock, d) provide first priority liens on all domestic business assets, e) maintain UTMD’s Interest Coverage Ratio at 1.15 to 1.00 or better, f) maintain UTMD’s Tangible Net Worth (TNW) above a minimum threshold 20% below TNW at closing on March 18, and g) maintain UTMD’s Leverage Ratio at 2.75 to 1.00 or less.  UTMD is in compliance with all of the loan covenants at June 30, 2013.  Based on UTMD’s financial position, the bank’s margin was 2.00% at June 30, 2013.  The principal balance on this note at June 30, 2013 was $3,850.

In March 2011, the Company also obtained a $12,934 loan from JP Morgan Chase, London Branch, to help finance UTMD’s purchase of Femcare. Terms and conditions of the UK loan are the same as those listed above for the $14,000 U.S. loan.  The principal balance on this note at June 30, 2013 was $6,693.

XML

Inventories: Schedule of Inventory, Current (Details) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Details
Finished goods	$ 1,487	$ 1,630
Work-in-process	1,031	938
Raw materials	1,849	1,785
Total	$ 4,367	$ 4,353

XML

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Statement of Cash Flows
Net income	$ 5,368	$ 5,190
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	308	334
Amortization	1,273	1,305
(Gain) loss on investments
Provision for (recovery of) losses on accounts receivable	(1)	8
(Gain)/Loss on disposal of assets	(1)
Deferred income taxes	(357)	(428)
Stock-based compensation expense	14	38
Changes in operating assets and liabilities:
Accounts receivable - trade	(1,350)	(275)
Accrued interest and other receivables	(128)	(89)
Inventories	8	183
Prepaid expenses and other current assets	145	62
Accounts payable	(17)	429
Accrued expenses	169	(170)
Deferred revenue	(50)	(50)
Other liability	(339)
Total adjustments	(326)	1,347
Net cash provided by operating activities	5,042	6,537
Capital expenditures for property and equipment	(111)	(133)
Capital expenditures for intangible assets	(5)	(1)
Purchases of investments
Proceeds from sale of investments
Net cash (used in) provided by investing activities	(116)	(134)
Proceeds from issuance of common stock - options	490	978
Common stock purchased and retired
Payment of taxes for exchange of stock options	(90)
Tax benefit attributable to exercise of stock options	199	99
Repayment of notes payable	(1,935)	(5,221)
Payment of dividends	(911)	(878)
Net cash provided by (used in) financing activities	(2,246)	(5,021)
Effect of exchange rate changes on cash	(164)	(3)
NET INCREASE IN CASH	2,514	1,378
CASH AT BEGINNING OF PERIOD	8,871	6,534
CASH AT END OF PERIOD	11,385	7,913
Cash paid during the period for income taxes	1,634	2,021
Cash paid during the period for interest	$ 235	$ 360

XML

Inventories

6 Months Ended

Jun. 30, 2013

Notes

Inventories

(2)    Inventories at June 30, 2013 and December 31, 2012 consisted of the following:

		June 30, 2013		December 31, 2012
Finished goods	$	1,487	$	1,630
Work-in-process		1,031		938
Raw materials		1,849		1,785
Total	$	4,367	$	4,353

XML

Warranty Reserve

6 Months Ended

Jun. 30, 2013

Notes

Warranty Reserve

(5)   Warranty Reserve.   The Company’s published warranty is: “UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment.  During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.”

UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2012 or June 30, 2013.

XML

Stock-Based Compensation

6 Months Ended

Jun. 30, 2013

Notes

Stock-Based Compensation

(3)           Stock-Based Compensation. The Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors.  The Company accounts for stock compensation under FASB Accounting Standards Codification (“ASC”) 718, Stock Compensation.  This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors.  In the quarters ended June 30, 2013 and 2012, the Company recognized $7 and $18 , respectively, in stock-based compensation cost.  In the six months ended June 30, 2013 and 2012, the Company recognized $14 and $38, respectively, in stock-based compensation cost.

XML

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET (Parenthetical) (USD $) In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Statement of Financial Position
Preferred Stock, Par Value	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized	5,000	5,000
Preferred Stock, Shares Issued
Preferred Stock, Shares Outstanding
Common Stock, Par Value	$ 0.01	$ 0.01
Common Stock, Shares Authorized	50,000	50,000
Common Stock, Shares Issued	3,728	3,703
Common Stock, Shares Outstanding	3,728	3,703

XML

Subsequent Events

6 Months Ended

Jun. 30, 2013

Notes

Subsequent Events

 (8)          Subsequent Events.  UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.

XML

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME (Parenthetical) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Income Statement
Foreign currency translation tax adjustment	$ 0	$ 0	$ 0	$ 0
Unrealized gain (loss) on investments tax adjustment	$ 2	$ (3)	$ 4	$ 3

XML

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Current assets:
Cash	$ 11,385	$ 8,871
Investments, available-for-sale	51	42
Accounts & other receivables - net	5,673	4,341
Inventories	4,367	4,353
Other current assets	813	929
Total current assets	22,289	18,535
Property and equipment - net	8,155	8,428
Goodwill	14,953	15,488
Other intangible assets	38,731	41,242
Other intangible assets - accumulated amortization	(7,699)	(6,758)
Other intangible assets - net	31,031	34,484
TOTAL ASSETS	76,429	76,935
Current liabilities:
Accounts payable	942	1,000
Accrued expenses	3,831	2,821
Current portion of notes payable	3,834	4,001
Total current liabilities	8,607	7,823
Notes payable	6,709	9,003
Deferred tax liability - intangible assets	7,583	7,889
Other long term liabilities	0	363
Deferred income taxes	889	884
TOTAL LIABILITIES	23,788	25,963
Stockholders' equity:
Preferred stock - $.01 par value; authorized - 5,000 shares; no shares issued or outstanding
Common stock - $.01 par value; authorized - 50,000 shares; issued - June 30, 2013, 3,728 shares and December 31, 2012, 3,703 shares	37	37
Accumulated other comprehensive loss	(3,343)	(851)
Additional paid-in capital	2,885	2,268
Retained earnings	53,062	49,519
Total stockholders' equity	52,641	50,972
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 76,429	$ 76,935

XML

Fair Value Measurements

6 Months Ended

Jun. 30, 2013

Notes

Fair Value Measurements

(7)  Fair Value Measurements.  The Company follows ASC 820, Fair Value Measurement to determine fair value of its financial assets.  The following table provides financial assets carried at fair value measured as of June 30, 2013:

			Fair Value Measurements Using
Description		Total Fair Value at 6/30/2013		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3 )
Equities	$	51	$	51	$	0	$	0

XML

Investments: Available-for-sale Securities (Tables)

6 Months Ended

Jun. 30, 2013

Tables/Schedules

Available-for-sale Securities

		2Q 2013		2Q 2012
Balance, beginning of period	$	3	$	(183)
Realized loss from securities included in beginning balance		~		~
Gross unrealized holding gains (losses), in equity securities		4		(8)
Deferred income taxes on unrealized holding (gain) loss		(2)		3
Balance, end of period	$	5	$	(188)

XML

Investments

6 Months Ended

Jun. 30, 2013

Notes

Investments

(6)   Investments.  As of June 30, 2013, the Company’s investments are in Citigroup (C).  Changes in the unrealized holding gain on investment securities available-for-sale and reported as a separate component of accumulated other comprehensive income are as follows:

		2Q 2013		2Q 2012
Balance, beginning of period	$	3	$	(183)
Realized loss from securities included in beginning balance		~		~
Gross unrealized holding gains (losses), in equity securities		4		(8)
Deferred income taxes on unrealized holding (gain) loss		(2)		3
Balance, end of period	$	5	$	(188)

XML

Basis of Presentation

6 Months Ended

Jun. 30, 2013

Notes

Basis of Presentation

(1)           The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States.  These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10 K for the year ended December 31, 2012.  In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations.  Currency amounts are in thousands except per-share amounts and where noted.

XML

Stock-Based Compensation (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Details
Allocated Share-based Compensation Expense	$ 7	$ 18	$ 14	$ 38

XML

Inventories: Schedule of Inventory, Current (Tables)

6 Months Ended

Jun. 30, 2013

Tables/Schedules

Schedule of Inventory, Current

		June 30, 2013		December 31, 2012
Finished goods	$	1,487	$	1,630
Work-in-process		1,031		938
Raw materials		1,849		1,785
Total	$	4,367	$	4,353

XML

Fair Value Measurements: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013
Fair Value, Inputs, Level 1
Equities	$ 51
Fair Value, Inputs, Level 2
Equities	0
Fair Value, Inputs, Level 3
Equities	0
Fair Value, Measurements, Recurring
Equities	$ 51

XML

Notes Payable (Details) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2013
JP Morgan Chase Bank NA (Chase) Note
Debt Instrument, Description	In March 2011, the Company obtained a $14,000 loan from JPMorgan Chase Bank, N.A. (Chase), to help finance the purchase of Femcare Group Ltd (Femcare) of the United Kingdom, and its subsidiaries. The terms and conditions of the loan require UTMD to a) repay the loan principal in equal monthly payments over 5 years, b) pay interest based on the 30-day LIBOR rate plus a margin starting at 2.80% and ranging from 2.00% to 3.75%, depending on the ratio of UTMD’s funded debt to EBITDA (Leverage Ratio), c) pledge 65% of all foreign subsidiaries’ stock, d) provide first priority liens on all domestic business assets, e) maintain UTMD’s Interest Coverage Ratio at 1.15 to 1.00 or better, f) maintain UTMD’s Tangible Net Worth (TNW) above a minimum threshold 20% below TNW at closing on March 18, and g) maintain UTMD’s Leverage Ratio at 2.75 to 1.00 or less. UTMD is in compliance with all of the loan covenants at June 30, 2013. Based on UTMD’s financial position, the bank’s margin was 2.00% at June 30, 2013. The principal balance on this note at June 30, 2013 was $3,850.
Debt Instrument, Face Amount	$ 14,000
Debt Instrument, Description of Variable Rate Basis	30-day LIBOR rate plus a margin starting at 2.80% and ranging from 2.00% to 3.75%
Debt Instrument, Basis Spread on Variable Rate	2.00%
Long-term Debt, Gross	3,850
JP Morgan Chase London Branch Note
Debt Instrument, Description	In March 2011, the Company also obtained a $12,934 loan from JP Morgan Chase, London Branch, to help finance UTMD’s purchase of Femcare. Terms and conditions of the UK loan are the same as those listed above for the $14,000 U.S. loan. The principal balance on this note at June 30, 2013 was $6,693.
Debt Instrument, Face Amount	12,934
Long-term Debt, Gross	$ 6,693

XML

Document and Entity Information (USD $)	6 Months Ended
	Jun. 30, 2013	Aug. 07, 2013
Document and Entity Information:
Entity Registrant Name	UTAH MEDICAL PRODUCTS INC
Document Type	10-Q
Document Period End Date	Jun. 30, 2013
Amendment Flag	false
Entity Central Index Key	0000706698
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		3,735,000
Entity Public Float	$ 177,627,000
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q2

XML

Investments: Available-for-sale Securities (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Details
Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses	$ 3	$ (183)
Realized loss from securities included in beginning balance
Available-for-sale Securities, Gross Unrealized Gain (Loss)	4	(8)
Deferred income taxes on unrealized holding (gain) loss	(2)	3
Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses	$ 5	$ (188)